Welcome to our dedicated page for Bwx Technologies news (Ticker: BWXT), a resource for investors and traders seeking the latest updates and insights on Bwx Technologies stock.
BWX Technologies, Inc. reports developments tied to its nuclear manufacturing, engineering, and services businesses for government and commercial customers. Recurring updates include U.S. Naval Nuclear Propulsion Program contracts, long-lead reactor and component manufacturing, commercial nuclear equipment, and work connected to nuclear fuel and uranium-enrichment capabilities.
Company news also covers operating and financial results for its Government Operations and Commercial Operations segments, capital actions, governance changes, and regulatory engagement involving nuclear licensing. BWXT’s recurring business themes span global security, clean energy, nuclear medicine, space exploration, and environmental restoration.
BWX Technologies, Inc. (NYSE: BWXT) announced its subsidiary, BWXT Medical Ltd., has entered a partnership with Bayer AG to develop Actinium-225 (Ac-225) supply and explore further commercialization opportunities for targeted radionuclide therapies (TRTs). Ac-225 is a potent radioisotope used in targeted alpha therapies for tumors. BWXT Medical aims to leverage its partnerships for processing and manufacturing at its facilities. This collaboration is expected to advance both companies' growth strategies in the expanding TRT market, which shows significant potential for future development.
NuScale Power is enhancing its manufacturing process at BWXT Canada Ltd.'s facility in Cambridge, Ontario, focusing on the fabrication of its NuScale Power Module™. This step is significant for the development of small modular reactor (SMR) technology and showcases NuScale's effort to establish a robust Canadian supply chain. BWXT Canada was engaged for an 18-month design contract, with further manufacturing agreements expected. The company emphasizes its capacity to source 80% of the plant components locally, aiming for Canadian deployment of the SMR technology by 2028.
BWX Technologies, Inc. (NYSE: BWXT) has secured a contract from Bruce Power worth approximately CA$40 million for the supply of four moderator heat exchangers. The contract will be implemented by BWXT Canada Ltd. at its Cambridge, Ontario facility, covering engineering and fabrication. Deliveries are planned for 2024 and 2025. This contract is expected to support a significant number of skilled jobs at BWXT’s Cambridge operations, contributing to reliable and non-emitting electricity generation in Ontario.
BWX Technologies reported Q2 2021 revenue of $505 million, unchanged from Q2 2020. Net income was $59.3 million or $0.62 per diluted share, down from $64.3 million or $0.67 per diluted share last year. The Nuclear Operations Group saw a 7% revenue decrease to $381 million, while the Nuclear Power Group's revenue surged 50% to $102 million. Despite cash from operations falling to $59.9 million from $162 million in Q2 2020, BWXT declared a quarterly dividend of $0.21 per share, payable on September 8, 2021.
BWX Technologies, Inc. (BWXT) is set to release its second quarter 2021 financial results on August 2, 2021, after the market closes. A conference call will follow at 5:00 p.m. EDT, allowing participants to join and access a supporting presentation online. BWXT, based in Lynchburg, Virginia, specializes in providing nuclear solutions across various sectors, employing approximately 6,700 individuals across 12 major sites in the U.S. and Canada. The company is involved in numerous joint ventures with the U.S. Department of Energy and NASA.
BWXT Medical Ltd. announced a long-term agreement with Boston Scientific to manufacture TheraSphere™ Y-90 Glass Microspheres, aimed at treating hepatocellular carcinoma (HCC). The deal includes substantial investment to automate production at BWXT's Ottawa facility, enhancing capacity to meet growing demand. This follows Boston Scientific's recent FDA PMA approval of TheraSphere, which increases patient access to this treatment. BWXT cautions that various risks may affect production and demand for TheraSphere.
BWX Technologies reported Q1 2021 revenue of $528 million, down 2.6% from $542 million in Q1 2020. Net income was $69.7 million ($0.73 per diluted share), a decrease from $75.5 million ($0.79 per diluted share) year-over-year. The Nuclear Operations Group faced a 5.1% revenue decline, while the Nuclear Power Group saw a 22% increase. The company generated $98.4 million in cash from operations, compared to a $6.4 million loss in Q1 2020, and declared a $0.21 dividend per share. BWXT reiterated 2021 guidance for revenue and non-GAAP EPS between $3.05 and $3.20.
BWX Technologies, Inc. (NYSE: BWXT) has enhanced its technical fellows initiative by selecting 25 new employees, recognizing their scientific and engineering contributions. The fellows, seen as senior technical leaders, will provide ongoing technical guidance and mentor future talent. This initiative aims to leverage expertise to strengthen workforce excellence and promote diversity in leadership. The program spans various business segments in the U.S. and Canada, focusing on areas like nuclear safety, automation, and engineering. BWXT is committed to fostering innovation and technical excellence.
BWX Technologies (NYSE: BWXT) has secured U.S. Naval Nuclear Propulsion Program contracts worth approximately $2.2 billion, including future options, for producing naval nuclear reactor components and fuel. This continues a long-standing partnership with the U.S. government spanning over 65 years. The contracts, initiated in 2021, will be fulfilled over an 8-year period across multiple facilities in Virginia, Ohio, and Indiana. The projects are vital for the Columbia and Virginia-class submarines, supporting U.S. strategic defense.
BWX Technologies, Inc. (BWXT) has announced a webcast to discuss its first quarter 2021 results on May 4, 2021, at 9:00 a.m. EDT. A press release detailing the results will follow after market close on May 3.
Listeners can join via www.bwxt.com/investors. Dial-in numbers for participants are (U.S.) 844-850-0542 and (International) 412-317-6014. A replay will be available on the BWXT website for a limited time.